{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:22:00Z","timestamp":1780950120267,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ECS00000017"],"award-info":[{"award-number":["ECS00000017"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PRA_2022-2023_12"],"award-info":[{"award-number":["PRA_2022-2023_12"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007514","name":"University of Pisa","doi-asserted-by":"publisher","award":["PRA_2022-2023_12"],"award-info":[{"award-number":["PRA_2022-2023_12"]}],"id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Inorganic Biochemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jinorgbio.2023.112452","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T18:35:27Z","timestamp":1701628527000},"page":"112452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cytotoxic auranofin analogues bearing phosphine, arsine and stibine ligands: A study on the possible role of the ligand on the biological activity"],"prefix":"10.1016","volume":"251","author":[{"given":"Ester","family":"Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Gamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gabbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Cirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinorgbio.2023.112452_bb0005","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.1039\/D0SC04082G","article-title":"Metallodrugs are unique: opportunities and challenges of discovery and development","volume":"11","author":"Anthony","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0015","doi-asserted-by":"crossref","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: past, present and future","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: the first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0025","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1039\/D2DT03483B","article-title":"A biophysical study of the interactions of palladium(ii), platinum(ii) and gold(iii) complexes of aminopyridyl-2,2\u2032-bipyridine ligands with RNAs and other nucleic acid structures","volume":"52","author":"Binacchi","year":"2023","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0030","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1039\/D1DT01492G","article-title":"Two mixed valence diruthenium(II,III) isomeric complexes show different anticancer properties","volume":"50","author":"Barresi","year":"2021","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0035","doi-asserted-by":"crossref","first-page":"14520","DOI":"10.1039\/D0DT02527E","article-title":"A mixed-valence diruthenium(ii,iii) complex endowed with high stability: From experimental evidence to theoretical interpretation","volume":"49","author":"Barresi","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10534-016-9962-0","article-title":"New gold carbene complexes as candidate anticancer agents","volume":"29","author":"Pratesi","year":"2016","journal-title":"BioMetals."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0045","article-title":"Highlights of new strategies to increase the efficacy of transition metal complexes for cancer treatments","volume":"28","author":"Giorgi","year":"2023","journal-title":"Molecules."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chempr.2019.10.013","article-title":"Classification of metal-based drugs according to their mechanisms of action","volume":"6","author":"Boros","year":"2020","journal-title":"Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0055","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1039\/D1CS00933H","article-title":"Recent development of gold(i) and gold(iii) complexes as therapeutic agents for cancer diseases","volume":"51","author":"Lu","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202218000","article-title":"Gold complexes in anticancer therapy: from new design principles to particle-based delivery systems","volume":"135","author":"Moreno-Alc\u00e1ntar","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1515\/pac-2018-0901","article-title":"Anticancer properties of gold complexes with biologically relevant ligands","volume":"91","author":"Fern\u00e1ndez-Moreira","year":"2019","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0070","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/med.21872","article-title":"Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness","volume":"42","author":"Gamberi","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108272","article-title":"Auranofin: past to present, and repurposing","volume":"101","author":"Yamashita","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0080","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/acsmedchemlett.9b00007","article-title":"Replacement of the Thiosugar of Auranofin with iodide enhances the anticancer potency in a mouse model of ovarian cancer","volume":"10","author":"Marzo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fchem.2020.00812","article-title":"Mechanistic insights into the anticancer properties of the Auranofin analog au(PEt3)I: a theoretical and experimental study","volume":"8","author":"Tolbatov","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/biomedicines9050504","article-title":"Strategies for the improvement of metal-based chemotherapeutic treatments","volume":"9","author":"Cirri","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0095","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/molecules28031050","article-title":"Chemical modification of Auranofin yields a new family of anticancer drug candidates: the gold(I) phosphite analogues","volume":"28","author":"Cirri","year":"2023","journal-title":"Molecules."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0100","doi-asserted-by":"crossref","first-page":"13527","DOI":"10.1039\/D2DT00836J","article-title":"Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent","volume":"51","author":"Cirri","year":"2022","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/acsmedchemlett.7b00162","article-title":"Auranofin, et 3 PAuCl, and et 3 PAuI are highly cytotoxic on colorectal cancer cells: a chemical and biological study","volume":"8","author":"Marzo","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0110","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s10534-019-00224-1","article-title":"Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin","volume":"32","author":"Cirri","year":"2019","journal-title":"BioMetals"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111079","article-title":"Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties","volume":"208","author":"Landini","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fphar.2018.00535","article-title":"Searching synergistic dose combinations for anticancer drugs","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide \u2014 an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0130","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1745-7254.2008.00818.x","article-title":"Perspectives of antimony compounds in oncology","volume":"29","author":"Sharma","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1021\/jm900185q","article-title":"Molecular basis of antimony treatment in Leishmaniasis","volume":"52","author":"Baiocco","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0140","series-title":"Encycl. Met","first-page":"78","article-title":"Antimony-based therapy of Leishmaniases, molecular and cellular rationale","author":"Colotti","year":"2013"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3891\/acta.chem.scand.41a-0173","article-title":"Crystal structures of Iodo(triphenylphosphine)gold(I) and Bis[iodo(trimethylphosphine)gold(I)]","volume":"41a","author":"Ahrland","year":"1987","journal-title":"Acta Chem. Scand."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0150","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1071\/CH9871545","article-title":"Lewis-base adducts of group I metal(I) compounds. XXVI. Solid-state cross-polarization magic-angle-spinning 31P N.M.R. and structural studies on 1:1 adducts of triphenylphosphine with gold(I) salts","volume":"40","author":"Barron","year":"1987","journal-title":"Aust. J. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.molstruc.2014.05.020","article-title":"Isomorphism in the structural chemistry of two-coordinate adducts of diphenyl(2-formylphenyl)phosphine and triphenylphosphine with gold(I) halides","volume":"1072","author":"Dunstan","year":"2014","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s10534-019-00210-7","article-title":"The leading established metal-based drugs: a revisitation of their relevant physico-chemical data","volume":"32","author":"Cirri","year":"2019","journal-title":"BioMetals."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bcp.2003.09.038","article-title":"Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c","volume":"67","author":"Rigobello","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.freeradbiomed.2018.03.043","article-title":"Significance of the mitochondrial thioredoxin reductase in cancer cells: an update on role, targets and inhibitors","volume":"127","author":"Scalcon","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0175","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2006.09.004","article-title":"On the potential of thioredoxin reductase inhibitors for cancer therapy","volume":"16","author":"Urig","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0180","series-title":"Bioinorganic and Medicinal Chemistry: Aspects of Gold(I)-Protein Complexes","author":"Bhabak","year":"2011"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0185","article-title":"Selective arylation of selenocysteine of thioredoxin reductase 1 by an organogold compound: expanding the tool-box of metal-templated reactions in cancer cells","author":"Skos","year":"2023","journal-title":"Chemistry"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0190","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1039\/D0DT00283F","article-title":"ESI MS studies highlight the selective interaction of Auranofin with protein free thiols","volume":"49","author":"Zoppi","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.733463","article-title":"Current progress and perspectives on using gold compounds for the modulation of tumor cell metabolism","volume":"9","author":"Kou","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0200","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0205","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1073\/pnas.2007285117","article-title":"Gold-based therapy: from past to present","volume":"117","author":"Balfourier","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jinorgbio.2014.01.009","article-title":"Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation","volume":"136","author":"Pratesi","year":"2014","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0215","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fchem.2020.00812","article-title":"Mechanistic insights into the anticancer properties of the Auranofin analog Au(PEt3)I: a theoretical and experimental study","volume":"8","author":"Tolbatov","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0220","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3390\/molecules27082578","article-title":"Anti-staphylococcal activity of the Auranofin analogue bearing acetylcysteine in place of the Thiosugar: an experimental and theoretical investigation","volume":"27","author":"Chiaverini","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0225","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1073\/pnas.100114897","article-title":"Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol\/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence","volume":"97","author":"Zhong","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jmb.2007.04.044","article-title":"The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis","volume":"370","author":"Fritz-Wolf","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0235","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1016\/S0277-5387(00)83654-2","article-title":"Gold(I) complexes with thiolate and triphenylphosphine ligands","volume":"11","author":"Delgado","year":"1992","journal-title":"Polyhedron."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0240","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/ol500385a","article-title":"S-Aroylthiooximes: a facile route to hydrogen sulfide releasing compounds with structure-dependent release kinetics","volume":"16","author":"Foster","year":"2014","journal-title":"Org. Lett."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0245","doi-asserted-by":"crossref","first-page":"2002044","DOI":"10.1002\/smll.202002044","article-title":"Is GSH chelated Pt molecule inactive in anti-cancer treatment? A case study of Pt 6 GS 4","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.581648","article-title":"Reactions of medicinal gold(III) compounds with proteins and peptides explored by electrospray ionization mass spectrometry and complementary biophysical methods","volume":"8","author":"Massai","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0255","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.1021\/acs.inorgchem.9b01900","article-title":"Structural characterization of a gold\/serum albumin complex","volume":"58","author":"Pratesi","year":"2019","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0260","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1021\/jm060436a","article-title":"Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands","volume":"49","author":"Casini","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.213905","article-title":"Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds","volume":"438","author":"Gamberi","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2019.03.015","article-title":"Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug","volume":"162","author":"Zhang","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0275","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ccr.2009.02.026","article-title":"Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs","volume":"253","author":"Bindoli","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S1600576714022985","article-title":"Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination","volume":"48","author":"Krause","year":"2015","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. C Struct. Chem."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0290","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1039\/C6DT03867K","article-title":"PtI 2 (DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features","volume":"46","author":"Cirri","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2023.112452_bb0295","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1021\/om100106e","article-title":"NMR chemical shifts of trace impurities: common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist","volume":"29","author":"Fulmer","year":"2010","journal-title":"Organometallics."}],"container-title":["Journal of Inorganic Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013423003343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013423003343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:59:16Z","timestamp":1778669956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0162013423003343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":59,"alternative-id":["S0162013423003343"],"URL":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2023.112452","relation":{},"ISSN":["0162-0134"],"issn-type":[{"value":"0162-0134","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytotoxic auranofin analogues bearing phosphine, arsine and stibine ligands: A study on the possible role of the ligand on the biological activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Inorganic Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2023.112452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112452"}}